- Home
- APRE vs RELI Comparison
APRE vs RELI Comparison
Compare APRE & RELI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- RELI
- Stock Information
- Founded
- APRE 2006
- RELI 2013
- Country
- APRE United States
- RELI United States
- Employees
- APRE N/A
- RELI N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- RELI Specialty Insurers
- Sector
- APRE Health Care
- RELI Finance
- Exchange
- APRE Nasdaq
- RELI Nasdaq
- Market Cap
- APRE 8.3M
- RELI 7.5M
- IPO Year
- APRE 2019
- RELI N/A
- Fundamental
- Price
- APRE $1.47
- RELI $1.01
- Analyst Decision
- APRE Strong Buy
- RELI
- Analyst Count
- APRE 1
- RELI 0
- Target Price
- APRE $20.00
- RELI N/A
- AVG Volume (30 Days)
- APRE 40.4K
- RELI 11.7M
- Earning Date
- APRE 11-06-2025
- RELI 11-06-2025
- Dividend Yield
- APRE N/A
- RELI N/A
- EPS Growth
- APRE N/A
- RELI N/A
- EPS
- APRE N/A
- RELI N/A
- Revenue
- APRE $841,012.00
- RELI $14,061,478.00
- Revenue This Year
- APRE N/A
- RELI N/A
- Revenue Next Year
- APRE N/A
- RELI N/A
- P/E Ratio
- APRE N/A
- RELI N/A
- Revenue Growth
- APRE N/A
- RELI 1.07
- 52 Week Low
- APRE $1.37
- RELI $0.67
- 52 Week High
- APRE $5.01
- RELI $5.11
- Technical
- Relative Strength Index (RSI)
- APRE 45.12
- RELI 53.73
- Support Level
- APRE $1.46
- RELI $0.89
- Resistance Level
- APRE $1.57
- RELI $1.15
- Average True Range (ATR)
- APRE 0.08
- RELI 0.21
- MACD
- APRE 0.01
- RELI 0.03
- Stochastic Oscillator
- APRE 54.45
- RELI 23.31
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About RELI Reliance Global Group Inc.
Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.